Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Kína3. fázis

Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)

A legfontosabb adatok

Ki végzi
Beijing Hospital of Traditional Chinese Medicine
Hol
Beijing, Chengdu, Chongqing, Guangzhou, Guizhou, Haozhou, Hebei, Heilongjiang, Hubei, Jinan, Kaifeng, Luoyang, Nanjing, Shanghai, Shanxi, Shaoyang, Shiyan, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xi’an, Xingtai, Yueyang, Zhejiang, Zhengzhou és Zhujiang (Kína)Mind a 29 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
636 fő, tervezett
Kezdés
2026. máj. 31.
Várható befejezés
2028. máj. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Chang Ji'an capsule
  • Chang Ji'an capsule mimic
A regiszteradat frissítve
2026. május 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with irritable bowel syndrome where diarrhea is the main problem. They must also fit the Traditional Chinese Medicine pattern called liver Qi invading the spleen.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Diarrhea-predominant irritable bowel syndrome (IBS-D). In the last week of the run-in period, the average score for abdominal pain, bloating or discomfort must be at least 3 on an 11-point scale. On at least 2 days that week, there must be at least one loose or watery stool (Bristol type 6 or 7). Anxiety score (SAS) must be under 60 and depression score (SDS) under 63.
Korábbi kezelés
A colonoscopy from the past 12 months at a tertiary hospital is needed. It must show no major problems. Small polyps (5mm or less, 3 or fewer) are allowed. No other IBS medicines in the 1 week before screening. No medicines that affect the gut in the 2 weeks before screening.

A részvétel fő kizáró okai

  • Other bowel diseases, such as inflammatory bowel disease, infections, bowel tumors or bleeding in the gut
  • Diabetes, overactive thyroid, serious heart, brain, liver, kidney or blood diseases, or abnormal liver or kidney tests
  • Past gut surgery, except appendix removal or removal of bowel polyps
  • Positive tests for hepatitis B, hepatitis C, HIV or syphilis
  • Pregnant or breastfeeding women, or people who will not use effective birth control

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Meet the Western medicine diagnostic criteria for diarrhea-predominant irritable bowel syndrome
  • Meet the Traditional Chinese Medicine syndrome differentiation criteria for liver Qi invading the spleen
  • Aged ≥18 and ≤65 years, regardless of gender
  • Record daily the most severe abdominal pain, bloating, and abdominal discomfort NRS scores for the last week of the run-in period. At least one of these three items must meet the weekly average NRS score criterion (the weekly average of abdominal pain NRS is calculated as: total weekly score of abdominal pain NRS on days with Bristol Stool Form Scale type 6 or 7 stools / actual number of days with Bristol type 6 or 7 stools in that week; the average values for the other two items are calculated similarly) ≥3 points (11-point Numerical Rating Scale, NRS-11); meanwhile, for stool form, during the last week of the run-in period, there must be at least 2 days in which each day has at least one bowel movement of Bristol type 6 or 7
  • Self-Rating Anxiety Scale (SAS) <60 points and Self-Rating Depression Scale (SDS) <63 points
  • Have a colonoscopy result showing no obvious abnormalities (including diverticula or chronic inflammation) or colon polyps, based on colonoscopy results within 12 months prior at a tertiary hospital: 1.Colonoscopy results are normal with no organic changes; 2. Colonoscopy report shows minor abnormalities such as hemorrhoids or colonic polyps (diameter ≤5mm and number ≤3), which the investigator deems eligible for inclusion; 3. Previous colonoscopy reported colonic polyps with diameter >5mm or number >3, but after endoscopic treatment within 6 months prior to screening, remaining polyps are ≤5mm in diameter and ≤3 in number, deemed eligible by the investigator
  • Agree to participate in this clinical trial and voluntarily sign the informed consent form

Ki nem vehet részt

  • Individuals who have used other medications for irritable bowel syndrome within 1 week prior to screening
  • Individuals who, within 2 weeks prior to screening, are using or need to continue using medications that may affect gastrointestinal function (anticholinergic drugs, 5-HT3 receptor antagonists, antidiarrheal drugs, antacids, prokinetic drugs, antidepressants (fluoxetine for at least 28 days), anti-anxiety drugs, intestinal microbiota regulators, traditional Chinese medicine decoctions, etc.)
  • Individuals who took emergency medication (Pivabromium tablets) during the last week of the induction period
  • Individuals who took prohibited medications during the induction period
  • Individuals confirmed to have infectious diarrhea, inflammatory bowel disease, parasitic infection, positive fecal occult blood tests and considered to have gastrointestinal bleeding (excluding hemorrhoids), colorectal tumors, malabsorption syndrome, lactose intolerance (based on medical history), and diarrhea caused by systemic diseases
  • Individuals with non-IBS-D or other organic gastrointestinal lesions (excluding superficial gastritis, grade I erosive gastritis, or chronic atrophic gastritis found on endoscopy but deemed by the investigator to be eligible for inclusion (e.g., no mucosal erosion or bleeding observed endoscopically, and the patient has no upper abdominal fullness, upper abdominal pain, or acid reflux)), or other organic lesions that the investigator judges may cause abdominal pain, bloating, or discomfort
  • Individuals with other mental disorders (excluding mild anxiety or depression)
  • Individuals with a history of gastrointestinal surgery (excluding appendectomy or intestinal polyp removal)
  • Individuals allergic to 3 or more medications or foods, or known allergies to Xiangjie Capsules and its components, as well as emergency medication Pivabromium tablets
  • Individuals suspected of or confirmed with a history of alcohol or drug abuse
  • Individuals with cognitive impairment unable to provide fully informed consent
  • Individuals positive for hepatitis B surface antigen, HIV antibody, hepatitis C antibody, or syphilis treponemal antibody
  • Individuals known to have familial colorectal cancer syndrome
  • Individuals with diabetes, hyperthyroidism, or serious primary diseases of the cardiovascular, cerebrovascular, liver, kidney, hematopoietic systems, or other serious diseases affecting survival (e.g., tumors), abnormal liver and kidney function (AST, ALT > 1.5 times the upper limit of normal reference range, Scr above the upper limit of normal reference range), and clinically significant ECG abnormalities
  • Pregnant women, breastfeeding women, or women of childbearing age planning to conceive; or female participants of childbearing potential and male participants (whose partners are women of childbearing potential) who do not agree to voluntarily use effective contraception from screening to 3 months after the last dose
  • Individuals with fewer than 3 spontaneous bowel movements per week during the induction period
  • Individuals with stool consistency of type 1 or 2 (Bristol Stool Form Scale) on at least 2 days per week during the induction period
  • Individuals who have participated in another clinical trial within the past month
  • Individuals who, in the opinion of the investigator, have other factors making them unsuitable for inclusion

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Helyszínek itt: Kína

  • Beijing Hospital of Traditional Chinese MedicineBeijing, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • West China Hospital,Sichuan UniversityChengdu, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Chongqing Traditional Chinese Medicine HospitalChongqing, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The First Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuizhou, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Haozhou People's HospitalHaozhou, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Hebei Provincial Hospital of Traditional Chinese MedicineHebei, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The First Affiliated Hospital of Heilongjiang University of Chinese MedicineHeilongjiang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Hubei Provincial Hospital of Traditional Chinese MedicineHubei, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The Affiliated Hospital of Shandong University of Traditional Chinese MedicineJinan, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Kaifeng Hospital of Traditional Chinese MedicineKaifeng, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Luoyang First People's HospitalLuoyang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Jiangsu Provincial Hospital of Traditional Chinese MedicineNanjing, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineShanghai, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The Affiliated Hospital of Shaanxi University of Chinese MedicineShanxi, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Shaoyang Central HospitalShaoyang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Shiyan People's HospitalShiyan, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The First Affiliated Hospital of Tianjin University of Traditional Chinese MedicineTianjin, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The Second Affiliated Hospital of Tianjin University of traditional Chinese MedicineTianjin, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Wenzhou Traditional Chinese Medicine HospitalWenzhou, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Wuxi Traditional Chinese Medicine HospitalWuxi, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Xi'an Central HospitalXi’an, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Xingtai People's HospitalXingtai, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese MedicineYueyang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Zhejiang Provincial Hospital of Traditional Chinese MedicineZhejiang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Zhengzhou First People's HospitalZhengzhou, KínaContact: LuQing Zhao, DoctorToborzás még nem indult
  • Zhujiang Hospital, Southern Medical UniversityZhujiang, KínaContact: LuQing Zhao, DoctorToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant irritable bowel syndrome (liver-qi invading spleen syndrome) after 8 weeks of treatment.

A vizsgálat 2 csoportja

  • Chang Ji'an capsule groupA vizsgált kezelés

    Chang Ji'an Capsules, 4 capsules each time, 3 times a day, orally

    Kezelés: Chang Ji'an capsule

  • Placebo groupPlacebo, összehasonlításként

    Chang Ji'an Capsules mimic, 4 capsules per dose, 3 times a day, orally

    Kezelés: Chang Ji'an capsule mimic

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07610434: ki vehet részt
A regiszteradat frissítve
2026. május 28.